Back to News
Market Impact: 0.25
Aptevo Therapeutics Inc. Reports Refined Priming-Dose Regimen for Mipletamig Ahead of Planned Phase 2 Development
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Aptevo Therapeutics reported that successive refinements to the priming-dose regimen for its lead drug candidate, mipletamig, substantially reduced infusion-related reactions. The provided article text gives no numerical magnitude or further clinical details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
APVO0.65
More News
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- Paraguay’s Santiago Pena under arrest, new president Pedro Alliana sworn in
- FIGS Beats Earnings as Demand Outstrips Supply, CEO Trina Spear Says
- OpenAI valued at $1.25 trillion, as rival Anthropic nears its IPO